Reminder: Oncology and NASH market info — Onc
Post# of 153897
(Total Views: 527)
Posted On: 10/31/2022 3:12:40 PM
Reminder: Oncology and NASH market info —
Oncology market = over half a trillion dollars:
https://www.gminsights.com/pressrelease/oncology-market
NASH market = nearly $200 billion:
https://www.biospace.com/article/non-alcoholi...-by-2028-/
Leronlimab and NASH:
“Researchers who conducted the NASH01 Clinical Study believe leronlimab has multiple mechanisms of action in people with NASH.”
“…compared with placebo, 350 mg of leronlimab weekly did cut average PDFF and cT1 change from baseline to week 14. Pooled analysis of people in trial parts 1 and 2 also showed significant drops in PDFF and cT1 at week 14 compared with placebo. The 350-mg dose of leronlimab significantly lowered cT1 from baseline to week 14 even in participants with moderate or severe cT1 values at baseline.”
“Compared with participants receiving placebo, those getting 350 mg of leronlimab weekly also had significant drops in ALT, AST, alkaline phosphatase and multiple markers of inflammation: VCAM, CCL2, CCL3, CCL5, CCL18, interferon gamma, IL-6, IL-8, IL-1 receptor antagonist. TNF receptor 2, and tissue inhibitor of MMP-1 and EN RAGE.”
“NASH01 investigators suggested leronlimab controls inflammation via multiple mechanisms involving VCAM, CCL2, CCL3, CCL11, and CCL18. Competitive binding of leronlimab to CCR5 may also contribute to antiinflammatory activity, they proposed.”
Oncology market = over half a trillion dollars:
https://www.gminsights.com/pressrelease/oncology-market
NASH market = nearly $200 billion:
https://www.biospace.com/article/non-alcoholi...-by-2028-/
Leronlimab and NASH:
“Researchers who conducted the NASH01 Clinical Study believe leronlimab has multiple mechanisms of action in people with NASH.”
“…compared with placebo, 350 mg of leronlimab weekly did cut average PDFF and cT1 change from baseline to week 14. Pooled analysis of people in trial parts 1 and 2 also showed significant drops in PDFF and cT1 at week 14 compared with placebo. The 350-mg dose of leronlimab significantly lowered cT1 from baseline to week 14 even in participants with moderate or severe cT1 values at baseline.”
“Compared with participants receiving placebo, those getting 350 mg of leronlimab weekly also had significant drops in ALT, AST, alkaline phosphatase and multiple markers of inflammation: VCAM, CCL2, CCL3, CCL5, CCL18, interferon gamma, IL-6, IL-8, IL-1 receptor antagonist. TNF receptor 2, and tissue inhibitor of MMP-1 and EN RAGE.”
“NASH01 investigators suggested leronlimab controls inflammation via multiple mechanisms involving VCAM, CCL2, CCL3, CCL11, and CCL18. Competitive binding of leronlimab to CCR5 may also contribute to antiinflammatory activity, they proposed.”
(11)
(0)